CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 3, 2007, Pages

  Herling, Andreas W ^a   Gossel, Matthias ^a   Haschke, Guido ^a   Stengelin, Siegfried ^a   Kuhlmann, Johanna ^a   Müller, Günter ^a   Schmoll, Dieter ^a   Kramer, Werner ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Cannabinoid receptors; Energy expenditure; Glycogenolysis; Lipolysis

Indexed keywords

AVE 1625; CANNABINOID RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE OXIDATION; GLYCOGEN ANALYSIS; GLYCOGEN LIVER LEVEL; GLYCOGENOLYSIS; LIPID OXIDATION; LIPOLYSIS; METABOLIC RATE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BODY WEIGHT; EATING; ENERGY INTAKE; ENERGY METABOLISM; HYDROCARBONS, HALOGENATED; LIPID PEROXIDATION; MALE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SULFONAMIDES;

EID: 34548417986     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00264.2007     Document Type: Article

References (45)

1. Anderwald C, Bernroider E, Krssak M, Stingl H, Brehm A, Bischof MG, Nowotny P, Roden M, Waldhausl W. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 51: 3025-3032, 2002.
2. Bachmann OP, Dahl DB, Brechtel K, Machann J, Haap M, Maier T, Loviscach M, Stumvoll M, Claussen CD, Schick F, Haring HU, Jacob S. Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 50: 2579-2584, 2001.
3. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63: 908-914, 2003.
4. Bergmeyer HU. Methoden der Enzymatischen Analyse. Weinheim, Germany: Verlag Chemie, 1974.
5. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50: 1612-1617, 2001.
6. Bonhaus DW, Chang LK, Kwan J, Martin GR. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287: 884-888, 1998.
7. Boschmann M, Frenz U, Noack R, Aust L, Murphy CM. Energy metabolism and metabolite patterns of rats after application of dexfenfluramine. Int J Obes Relat Metab Disord 18: 235-242, 1994.
8. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24: 2708-2715, 2004.
9. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423-431, 2003.
10. Coutts AA, Irving AJ, Mackie K, Pertwee RG, navi-Goffer S. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 448: 410-422, 2002.
11. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-2134, 2005.
12. DiMarzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585-589, 2005.
13. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 37: 287-301, 1988.
14. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066, 2003.
15. Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 86: 5755-5761, 2001.
16. Haslam DW, James WP. Obesity. Lancet 366: 1197-1209, 2005.
17. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291: 2847-2850, 2004.
18. Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am J Med 120: S18-S28, 2007.
19. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47, Suppl 1: 345-358, 2004.
20. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD, Haring HU. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48: 1113-1119, 1999.
21. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Javier Diaz-Molina F, Ripoll C, Rodriguez de Fonseca F, Nadal A. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 39: 155-162, 2006.
22. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42: 113-116, 1999.
23. Kulkarni-Narla A, Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 302: 73-80, 2000.
24. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord 29: 183-187, 2005.
25. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84: 1513-1517, 1999.
26. Marsicano G, Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest 29: 27-46, 2006.
27. Mato S, Pazos A, Valdizan EM. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Eur J Pharmacol 443: 43-46, 2002.
28. Niederhoffer N, Hansen HH, Fernandez-Ruiz JJ, Szabo B. Effects of cannabinoids on adrenaline release from adrenal medullary cells. Br J Pharmacol 134: 1319-1327, 2001.
29. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 43: 533-549, 2000.
30. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298-1305, 2005.
31. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462, 2006.
32. Pagotto U, Pasquali R. Endocannabinoids and energy metabolism. J Endocrinol Invest 29: 66-76, 2006.
33. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147, Suppl 1: S163-S171, 2006.
34. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761-775, 2006.
35. Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR, Mascolo N, Di Marzo V, Capasso F. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123: 227-234, 2002.
36. Porcella A, Marchese G, Casu MA, Rocchitta A, Lai ML, Gessa GL, Pani L. Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. Eur J Endocrinol 147: 255-261, 2002.
37. Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol 35: 93-99, 2006.
38. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF, Haffaf Y, Cesari M, Festy F. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 126: 177-187, 2006.
39. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49: 749-758, 2000.
40. Schutz Y, Ravussin E. Respiratory quotients lower than 0.70 in ketogenic diets. Am J Clin Nutr 33: 1317-1319, 1980.
41. Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med 142: 56-66, 2005.
42. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG. The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 426: R3-R4, 2001.
43. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389-1397, 2005.
44. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, Vehkavaara S, Goto T, Halavaara J, Hakkinen AM, Yki-Jarvinen H. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 50: 2337-2343, 2001.
45. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 109: 1-9, 1949.